Leukemias, lymphomas, and other hematologic cancers:
Indications for: ZOLINZA
Refractory cutaneous T-cell lymphoma.
Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated.
<18yrs: not established.
Prior history of thromboembolism; monitor for DVT, PE. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Diabetes. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1st 2 months, then monthly. Hepatic impairment. Embryo-fetal toxicity. Pregnancy: exclude status within 7 days prior to initiation. Use effective contraception during and for ≥6months (females) or ≥3months (males w. female partners) after the last dose. Nursing mothers: not recommended (during and for ≥1week after the last dose).
Histone deacetylase inhibitor.
Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid); monitor. Concomitant warfarin: monitor PT, INR frequently.
GI symptoms (eg, diarrhea, nausea, anorexia, weight decrease, vomiting, constipation), fatigue, chills, thrombocytopenia, anemia (may need to modify dose or discontinue), dysgeusia, dry mouth; PE, DVT, hyperglycemia.